Eli Lilly & Co. (LLY) Given "Hold" Rating by Citigroup (C) Analysts
Monday, June 27, 2021 12:10 PM

Equities research analysts at Citigroup (NYSE: C) reiterated a "hold" rating on shares of Eli Lilly & Co. (NYSE: LLY) in a research note to investors on Monday.

Separately, analysts at Barclays Capital (NYSE: BCS) raised their price target on shares of Eli Lilly & Co. from $39.00 to $42.00 in a research note to investors on Friday, May 27th. They now have an "equal weight" rating on the stock. Also, analysts at Goldman Sachs (NYSE: GS) raised their price target on shares of Eli Lilly & Co. to $35.00 in a research note to investors on Wednesday, May 18th. They now have a "sell" rating on the stock.

Shares of Eli Lilly & Co. traded up 0.27% during mid-day trading on Tuesday, hitting $36.86. Eli Lilly & Co. has a 52 week low of $32.27 and a 52 week high of $39.40. The stock's 50-day moving average is $37.43 and its 200-day moving average is $35.45. The company has a market cap of $40.988 billion and a price-to-earnings ratio of 8.36.

Eli Lilly & Co. last announced its quarterly results on Monday, April 18th. The company reported $1.24 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $1.16 EPS by $0.08. During the same quarter in the prior year, the company posted $1.18 earnings per share. The company’s quarterly revenue was up 6.40% on a year-over-year basis. On average, analysts predict that Eli Lilly & Co. will post $1.09 EPS next quarter.

Eli Lilly and Company discovers, develops, manufactures, and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries. Its products are sold in approximately 128 countries. The Company’s products include Neuroscience products, Endocrinology products, Oncology products, Cardiovascular products, Animal health products, and other pharmaceuticals. In the United States, Eli Lilly and Company distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies. In July 2010, the Company acquired Alnara Pharmaceuticals, Inc. In December 2010, the Company completed the acquisition of Avid Radiopharmaceuticals, Inc.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.